PLLBA-01 PEMBROLIZUMAB (PEMBRO) VS PLACEBO AS POST NEPHRECTOMY ADJUVANT THERAPY FOR PATIENTS (pts) WITH RENAL CELL CARCINOMA (RCC): RANDOMIZED, DOUBLE-BLIND, PHASE 3 KEYNOTE-564 STUDY

Autor:	Balaji Venugopal, Jaroslav Hajek, Naomi B. Haas, Se Hoon Park, Mauricio Mahave, Pingye Zhang, David I. Quinn, Yen-Hwa Chang, Jae-Lyun Lee, Piotr Sawrycki, Thomas W. Ferguson, Kentaro Imai, Toni K. Choueiri, Thomas Powles, Stefan Symeonides, Antoine Thiery-Vuillemin, Piotr Tomczak, Jaqueline Willemann-Rogerio, Marine Gross-Goupil, Naveed Sarwar
Rok vydání:	2021
Předmět:	medicine.medical_specialty business.industry Urology medicine.medical_treatment Pembrolizumab medicine.disease Placebo Nephrectomy Unmet needs Double blind Renal cell carcinoma medicine Adjuvant therapy bacteria business Adjuvant
Zdroj:	Journal of Urology. 206
ISSN:	1527-3792 0022-5347
DOI:	10.1097/ju.0000000000002150.01
Popis:	INTRODUCTION AND OBJECTIVE:Effective therapy to reduce risk of RCC relapse after surgery remains an unmet need. Adjuvant immune therapy is a potential strategy for these pts. The KEYNOTE-564 trial ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f8c86153227ecbe58292896e495e0129 https://doi.org/10.1097/ju.0000000000002150.01 Zobrazit plný text záznamu